Exact Mass: 347.1376012
Exact Mass Matches: 347.1376012
Found 147 metabolites which its exact mass value is equals to given mass value 347.1376012,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
EVOXINE
C18H21NO6 (347.13688060000004)
Desmethylofloxacin
C17H18FN3O4 (347.12812800000006)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
Nafamostat
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D051056 - Complement Inactivating Agents COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D006401 - Hematologic Agents > D000925 - Anticoagulants C471 - Enzyme Inhibitor > C783 - Protease Inhibitor D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Naproxcinod
C18H21NO6 (347.13688060000004)
(+)-4-(6-methoxy-9-methyl-8-oxo-8,9-dihydro-[1,3]dioxolo[4,5-h]quinolin-7-yl)-2-methyl-butyric acid methyl ester|Pteleolin|Pteleoline
C18H21NO6 (347.13688060000004)
(2S)-1-[(6,7-dimethoxyfuro[2,3-b]quinolin-4-yl)oxy]-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
Ala Gly Asn Ser
Ala Gly Ser Asn
Ala Asn Gly Ser
Ala Asn Ser Gly
Ala Ser Gly Asn
Ala Ser Asn Gly
Gly Ala Asn Ser
Gly Ala Ser Asn
Gly Gly Asn Thr
Gly Gly Gln Ser
Gly Gly Ser Gln
Gly Gly Thr Asn
Gly Asn Ala Ser
Gly Asn Gly Thr
Gly Asn Ser Ala
Gly Asn Thr Gly
Gly Gln Gly Ser
Gly Gln Ser Gly
Gly Ser Ala Asn
Gly Ser Gly Gln
Gly Ser Asn Ala
Gly Ser Gln Gly
Gly Thr Gly Asn
Gly Thr Asn Gly
Asn Ala Gly Ser
Asn Ala Ser Gly
Asn Gly Ala Ser
Asn Gly Gly Thr
Asn Gly Ser Ala
Asn Gly Thr Gly
Asn Ser Ala Gly
Asn Ser Gly Ala
Asn Thr Gly Gly
Gln Gly Gly Ser
Gln Gly Ser Gly
Gln Ser Gly Gly
Ser Ala Gly Asn
Ser Ala Asn Gly
Ser Gly Ala Asn
Ser Gly Gly Gln
Ser Gly Asn Ala
Ser Gly Gln Gly
Ser Asn Ala Gly
Ser Asn Gly Ala
Ser Gln Gly Gly
Thr Gly Gly Asn
Thr Gly Asn Gly
Thr Asn Gly Gly
1-naphthyl-n-acetyl-beta-d-glucosaminide
C18H21NO6 (347.13688060000004)
Boc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(R)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
2H-Pyrrol-2-one, 4-acetyl-1-(3-chloro-4-methylphenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-
C19H22ClNO3 (347.1288132000001)
6-Chloro-2,3,4,5-tetrahydro-7,8-dimethoxy-1-(4-methoxyphenyl)-1H-3-benzazepine
C19H22ClNO3 (347.1288132000001)
Boc-(R)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(3-trifluoromethyl-phenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-TOSYL-1H-PYRROLE
C17H22BNO4S (347.13625220000006)
Methanone, [4-(5-chloro-2-methylphenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)
C18H22ClN3O2 (347.14004620000003)
Methanone, [4-(3-chlorophenyl)-1-piperazinyl][3-methyl-5-(1-methylethyl)-4-isoxazolyl]
C18H22ClN3O2 (347.14004620000003)
6-AMINO-1-[3-(CYCLOPENTYLOXY)-4-METHOXYBENZYL]-2-THIOXO-2,3-DIHYDROPYRIMIDIN-4(1H)-ONE
C17H21N3O3S (347.13035560000003)
1-benzyl-4-(2-methoxy-phenyl)-pyrrolidine-3-carboxylic acid hydrochloride
C19H22ClNO3 (347.1288132000001)
trans-1-Benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
C19H22ClNO3 (347.1288132000001)
ethyl 2-piperazine-4-(4-methoxy)phenyl thiazole-5-carboxylate
C17H21N3O3S (347.13035560000003)
N-[(2S)-3-Amino-2-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]acetamide hydrochloride (1:1)
C15H23ClFN3O3 (347.14118900000005)
3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-TOSYL-1H-PYRROLE
C17H22BNO4S (347.13625220000006)
nalorphine hydrochloride ciii (250 mg)
C19H22ClNO3 (347.1288132000001)
naproxcinod
C18H21NO6 (347.13688060000004)
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D002317 - Cardiovascular Agents > D020030 - Nitric Oxide Donors C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
N2-(2-methoxyphenyl)-6-(3-methyl-2-benzofuranyl)-1,3,5-triazine-2,4-diamine
(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
C18H21NO6 (347.13688060000004)
Nafamostat
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D051056 - Complement Inactivating Agents COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D006401 - Hematologic Agents > D000925 - Anticoagulants C471 - Enzyme Inhibitor > C783 - Protease Inhibitor D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
BSPBio_000729
C18H21NO6 (347.13688060000004)
1-[4-(3,5-Dimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide
C17H21N3O3S (347.13035560000003)
1-(3-Methoxyphenyl)-3-[5-(2-methyl-1-piperidinyl)-1,3,4-thiadiazol-2-yl]urea
C16H21N5O2S (347.14158860000003)
5-[[3-Methyl-1-(4-methylphenyl)-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one
N-[(4-tert-butylcyclohexylidene)amino]-3-chloro-5-(trifluoromethyl)-2-pyridinamine
3-[(2,5-Dimethoxyphenyl)iminomethyl]-1,5-dioxaspiro[5.5]undecane-2,4-dione
C18H21NO6 (347.13688060000004)
Butyl N-trifluoroacetyl 2-N-methylaminoethyl phosphonate
Dibutyl 1-(N-trifuoroacetylamino)propylphosphonate
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
(2R)-1-[(4,8-dimethoxy-7-furo[2,3-b]quinolinyl)oxy]-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
1-naphthyl N-acetyl-beta-D-glucosaminide
C18H21NO6 (347.13688060000004)
An N-acetyl-beta-D-glucosaminide in which the anomeric hydroxy hydrogen is replaced by a 1-naphthyl group.